Santhera Pharmaceuticals Holding AG has raised CHF 27.7 million (€25.79 million) from new and existing investors for the anticipated launch of Raxone, a product for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), an inherited form of vision loss.
